Thyme Care Secures $95 Million in Series C Funding to Revolutionize Oncology Management

Thyme Care, a trailblazer in value-based oncology management, has announced a significant funding milestone, securing a robust $95 million in its latest financing round. This investment, backed by esteemed venture firms including Andreessen Horowitz (a16z), AlleyCorp, Frist Cressey Ventures, Casdin Capital, and Bessemer, positions Thyme Care to further its mission of enhancing the quality of life for individuals diagnosed with cancer. By leveraging a unique blend of human guidance and innovative technology, Thyme Care is redefining cancer care through personalized, clinically-coordinated support that effectively connects patients with the right resources. The funding will enable the expansion of their platform, facilitating deeper collaboration with health insurance plans and providers while integrating seamlessly into existing healthcare infrastructures. This approach not only prioritizes exceptional patient outcomes but also aims to reduce costs and enhance the overall member experience through risk-based payment arrangements. With its founder team comprising seasoned oncology experts and clinicians, Thyme Care is set to unlock high-value care tailored to the unique needs of cancer patients. As part of its commitment to revolutionizing the oncology care landscape, Thyme Care continues to focus on implementing targeted, evidence-based interventions that provide ongoing support for patients throughout their treatment journey. For more information on how Thyme Care is making strides in enabling high-quality cancer care, visit www.thymecare.com.